(Q36363579)

13 August 2017

1 reference

title

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data (English)

1 reference

13 August 2017

0 references

1 reference

Pedro N Aguiar

1

1 reference

13 August 2017

Ramon Andrade De Mello

2

1 reference

13 August 2017

Peter Hall

3

1 reference

13 August 2017

Hakaru Tadokoro

4

1 reference

13 August 2017

Gilberto de Lima Lopes

5

1 reference

13 August 2017

publication date

1 May 2017

1 reference

13 August 2017

1 reference

13 August 2017

volume

9

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

499-506

1 reference

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0150

21 January 2018

Identifiers

DOI

10.2217/IMT-2016-0150

1 reference

13 August 2017

1 reference